nimodipine has been researched along with Depression, Endogenous in 9 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Placebo-controlled, randomized, double-blind trial of nimodipine compared with placebo in out-of-hospital ventricular fibrillation." | 5.07 | Neuropsychological sequelae of cardiac arrest. ( Kajaste, S; Kaste, M; Roine, RO, 1993) |
| "Nimodipine pretreatment attenuated the perceived similarity of ketamine effects to ethanol as well as ketamine-induced euphoria and sedation." | 2.70 | Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists. ( Burakov, AM; Fletcher, J; Grinenko, AY; Grinenko, NI; Krupitsky, EM; Krystal, JH; Petrakis, IL; Romanova, TN, 2001) |
| "Nimodipine (NMD) is a Ca(2+) channel blocker that has been extensively investigated for therapy of central nervous system (CNS) disorders." | 1.43 | Antidepressant-like activity of liposomal formulation containing nimodipine treatment in the tail suspension test, forced swim test and MAOB activity in mice. ( Freitas, RM; Moreno, LCGEAI; Rolim, HML; Santos-Magalhães, NS, 2016) |
| " When the calcium antagonist nimodipine was given at a dosage quickly escalated to 360 mg daily, the patient could be discharged in a state of complete remission after 26 days." | 1.29 | [Phase prevention in bipolar affective disorder with nimodipine. A case report]. ( Berger, M; Hellwig, B; Hesslinger, B; Riedel, H; Walden, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moreno, LCGEAI | 1 |
| Rolim, HML | 1 |
| Freitas, RM | 1 |
| Santos-Magalhães, NS | 1 |
| De León, OA | 1 |
| Taragano, FE | 2 |
| Bagnatti, P | 2 |
| Allegri, RF | 1 |
| Pazzaglia, PJ | 2 |
| Post, RM | 2 |
| Ketter, TA | 2 |
| George, MS | 2 |
| Marangell, LB | 2 |
| Roine, RO | 1 |
| Kajaste, S | 1 |
| Kaste, M | 1 |
| Hesslinger, B | 1 |
| Riedel, H | 1 |
| Hellwig, B | 1 |
| Walden, J | 1 |
| Berger, M | 1 |
| Callahan, AM | 1 |
| Frye, MA | 1 |
| Kimbrell, TA | 1 |
| Leverich, GS | 1 |
| Cora-Locatelli, G | 1 |
| Luckenbaugh, D | 1 |
| Allegri, R | 1 |
| Vicario, A | 1 |
| Lyketsos, CG | 1 |
| Krupitsky, EM | 1 |
| Burakov, AM | 1 |
| Romanova, TN | 1 |
| Grinenko, NI | 1 |
| Grinenko, AY | 1 |
| Fletcher, J | 1 |
| Petrakis, IL | 1 |
| Krystal, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Depression Occurring in the Setting of Cerebrovascular Risk -- A Pilot Study[NCT00781326] | Phase 4 | 9 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Final cost of study medication was significantly greater than initial estimate,) | ||
| Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department[NCT04260607] | Phase 3 | 2 participants (Actual) | Interventional | 2020-01-14 | Terminated (stopped due to As a busy MTF we were unable to retain a health care provider with the appropriate expertise to buy-in to this study once the initiating PI left military service.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hamilton Depression Rating Scale (24 item) measures symptoms of major depression. We report total score which is the sum of all items. Total score range is 0 to 76 with higher scores indicating more severe depression. We reports scores at end of Phase I for subjects completing the phase. (NCT00781326)
Timeframe: End of Phase I (at 24 weeks)
| Intervention | units on a scale (Mean) |
|---|---|
| Open Label Antidepressant | 9.5 |
6 trials available for nimodipine and Depression, Endogenous
| Article | Year |
|---|---|
A double-blind, randomized clinical trial to assess the augmentation with nimodipine of antidepressant therapy in the treatment of "vascular depression".
Topics: Aged; Antidepressive Agents, Second-Generation; Argentina; Calcium Channel Blockers; Cerebrovascular | 2005 |
Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation.
Topics: Adult; Bipolar Disorder; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; | 1993 |
Neuropsychological sequelae of cardiac arrest.
Topics: Adult; Aged; Aged, 80 and over; Cognition; Depressive Disorder; Double-Blind Method; Female; Heart A | 1993 |
Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Carbamazepine; Depressive Disor | 1998 |
A double blind, randomized clinical trial assessing the efficacy and safety of augmenting standard antidepressant therapy with nimodipine in the treatment of 'vascular depression'.
Topics: Aged; Analysis of Variance; Antidepressive Agents; Calcium Channel Blockers; Cerebrovascular Disorde | 2001 |
Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists.
Topics: Adult; Affect; Alcoholism; Anxiety; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Ty | 2001 |
3 other studies available for nimodipine and Depression, Endogenous
| Article | Year |
|---|---|
Antidepressant-like activity of liposomal formulation containing nimodipine treatment in the tail suspension test, forced swim test and MAOB activity in mice.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tri | 2016 |
Response to nimodipine in ultradian bipolar cycling after amygdalohippocampectomy.
Topics: Antimanic Agents; Bipolar Disorder; Calcium Channel Blockers; Carbamazepine; Depressive Disorder; Fe | 2012 |
[Phase prevention in bipolar affective disorder with nimodipine. A case report].
Topics: Bipolar Disorder; Calcium Channel Blockers; Depressive Disorder; Dose-Response Relationship, Drug; D | 1996 |